---
layout: default
title: Aluminum Corn Silk Inula Helenium Root Sarsaparill
parent: 僅模型預測 (L5)
nav_order: 259
evidence_level: L5
indication_count: 0
---

# Aluminum Corn Silk Inula Helenium Root Sarsaparill
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ALUMINUM / CORN SILK / INULA HELENIUM ROOT / SARSAPARILLA / SILVER / VALERIAN: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This is a multi-ingredient combination comprising aluminum, corn silk, inula helenium root, sarsaparilla, silver, and valerian — none of which could be mapped to a DrugBank ID in the current pipeline.
The TxGNN model returned **no repurposing predictions** for this compound, as the absence of a structured drug record prevents the knowledge graph from generating disease associations.
This report serves as a data gap assessment; a full repurposing evaluation cannot be completed until foundational drug data is resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assessable (no prediction generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Was Generated

This compound is a **six-ingredient combination** spanning inorganic minerals (aluminum, silver) and botanical extracts (corn silk, inula helenium root, sarsaparilla, valerian). Each ingredient has a distinct pharmacological profile from traditional medicine contexts:

- **Corn Silk** (*Zea mays* stigma): used traditionally for urinary tract support and diuresis
- **Inula Helenium Root** (Elecampane): traditionally used for respiratory conditions; contains inulin and alantolactone with reported antimicrobial activity
- **Sarsaparilla** (*Smilax* spp.): used in traditional systems for inflammatory joint and skin conditions
- **Valerian** (*Valeriana officinalis*): widely recognized as a mild anxiolytic and sleep aid, acting on GABA pathways
- **Aluminum / Silver**: inorganic compounds with varying roles (antacid, antimicrobial) depending on formulation context

The core obstacle to TxGNN prediction is the **absence of a DrugBank ID**. The knowledge graph underlying TxGNN requires a recognized drug node (linked to targets, pathways, and known disease associations) to compute repurposing scores. A multi-ingredient formula of this type — particularly one containing unregistered or traditional herbal components — cannot be placed on the graph as a single entity.

Without mechanism of action data, known molecular targets, or approved indication anchors, there is no computational basis on which to generate or interpret a disease association score.

---

## Safety Considerations

No drug interaction data, contraindications, or regulatory warnings were identified for this combination in the current query. Please refer to the prescribing information or product monograph of each individual ingredient for safety guidance.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The combination lacks a DrugBank ID, has no approved indication in any queried jurisdiction, has no registered market status, and produced no TxGNN repurposing predictions. The data gaps are structural — meaning they block the pipeline at its earliest stage — and cannot be resolved by supplementary literature search alone.

**To proceed, the following is needed:**

- **Per-ingredient DrugBank mapping**: Decompose the combination and query TxGNN predictions for each active ingredient individually (e.g., valerian → DB04575, sarsaparilla sapogenins, inulin from Inula)
- **Clarify product identity**: Determine whether this combination corresponds to a specific marketed product in any jurisdiction (e.g., a homeopathic, Ayurvedic, or traditional Chinese medicine registration) and obtain the corresponding dossier
- **Establish an original indication**: Without a reference indication, the "From X to Y" repurposing framing cannot be applied; identify the intended therapeutic use from the product label or formulator documentation
- **Obtain MOA data**: At minimum, characterize the primary active constituent per ingredient and its known molecular mechanism before re-attempting repurposing analysis
- **Regulatory status verification**: Confirm whether any jurisdiction (US, EU, Taiwan, or others) has approved or registered a product with this exact composition
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

